Articles

Facilitating Progress and Innovation at AVBCC Summit

Value-based pharmaceutical design, government plans for CMS, and discussion of incentivizing high-value, low-cost care, are a few of the things to prioritize for future meetings, said Lelan Wilfong, MD, VP, Payer Relations & Value-Based Transformation, McKesson Specialty Health.

By Lalan Wilfong, MD

PATHFINDER Study Reveals Potential for Avapritinib to Modify Progression of Advanced Systemic Mastocytosis

Lelan Wilfong, MD, VP, Payer Relations & Value-Based Transformation, McKesson Specialty Health, says his colleagues should attend AVBCC because it is a great place to come together to facilitate the process of innovation.

Avapritinib Effectively Manages Advanced Systemic Mastocytosis in Patients with KIT D816V Mutations

Avapritinib was recently approved for treatment in advanced systemic mastocytosis after demonstrating in clinicals trials the ability to improve hematologic and bone marrow responses in patients.

Medicare Patients with Advanced Systemic Mastocytosis Have a Higher Financial Burden and Use More Healthcare Resources

KIT D816V mutations are highly associated with most cases of systemic mastocytosis. Avapritinib demonstrates efficacy in controlling disease progression in patients with KIT D816V mutations.

Assessment of Prognostic Scoring Tools for Systemic Mastocytosis in a Real-World Setting

Advanced systemic mastocytosis often develops in patients aged >60 years but some younger patients qualify for Medicare due to preexisting disability. All patients with advanced systemic mastocytosis require more healthcare resources and have greater medical costs.

New Study Investigates Safety and Efficacy of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

Clinical trials in systemic mastocytosis have led to the development of new prognostic scoring systems. Although effective in a controlled study, their usefulness in identifying high-risk patients in a real-world clinical setting requires further evaluation.

The AVBCC Summit Is for Everyone

Bezuclastinib treatment has shown clinical activity in advanced solid tumors with little toxicity. A phase 2 investigation seeks to determine its potential as a safe and effective option for KIT D816V–driven advanced systemic mastocytosis.

By Elizabeth Beisel

Insights into Research Funding at AVBCC Summit

Elizabeth Beisel, Swim Across America Representative, attended the AVBCC Summit to learn from some of the "most brilliant minds" in cancer care today after having lost her father to pancreatic cancer earlier in the year.

By Elizabeth Beisel